local
With FDA approval, Celcuity sees big future for its new breast cancer drug
Summary by The Minneapolis Editorial Desk · Based on reporting from Star Tribune
· July 22, 2026
· 1 min read
Despite stock dips, the Minnesota biotech firm thinks its innovative therapy and strong results can compete in multibillion dollar markets for cancer treatment.
Story provenance No corrections
Summary created by The Minneapolis Editorial Desk — automated, rule-governed Original reporting Star Tribune Original story Read at the source Source published Jul 22, 2026 Indexed here Jul 22, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Why this matters in The Minneapolis
The FDA approval of Celcuity's new breast cancer drug brings significant potential to the Minnesota biotech scene, where the company's innovative therapy could carve out a substantial share of the multibillion dollar cancer treatment market. As a local firm, Celcuity's success would not only boost the state's economy but also contribute to the Twin Cities' growing reputation as a hub for medical innovation. The company's strong results and competitive edge could attract more investment and talent to the area, further solidifying Minneapolis-St. Paul's position in the biotech industry. With the University of Minnesota and other research institutions in the area, Celcuity's breakthrough could also lead to collaborations and partnerships that drive further advancements in cancer treatment and beyond. As the company moves forward, its progress will be closely watched by local business leaders, researchers, and patients who stand to benefit from its innovative therapy.
About this story
Original reporting by Star Tribune . The Minneapolis surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Star Tribune . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: July 22, 2026 ·
Source: Star Tribune ·
Reading time: 1 min
Frequently asked about this story
What is this story about? Despite stock dips, the Minnesota biotech firm thinks its innovative therapy and strong results can compete in multibillion dollar markets for cancer treatment.
When was this published? This article was first published on July 22, 2026 by Star Tribune and curated for The Minneapolis readers.
Who reported this story? This story was reported by Star Tribune. To learn more about how The Minneapolis selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from The Minneapolis, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter